Misty Rayna Jenkins

Lab Head

Walter and Eliza Hall Institute of Medical Research

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Immunology Immunology professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Misty Rayna Jenkins is the Lab Head at the Walter and Eliza Hall Institute of Medical Research in Australia. Her research focuses on the extracellular matrix in brain cancer immunotherapy, transcriptomics in cancer research, and genomic health policies. Recent publications include work on CAR T-cell therapy, glioblastoma treatments, and the genomic diversity among Indigenous Australians.

Articles (18)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (21)

Terrance Johns

Centre & Head of Oncogenic Signalling Laboratory

Telethon Kids Institute

AUSTRALIA

Misty Rayna Jenkins

Research Interests

Explore related searches

Contact this professor

About

Articles (18)

Defining the extracellular matrix for targeted immunotherapy in adult and pediatric brain cancer.

TIRE-seq simplifies transcriptomics via integrated RNA capture and library preparation.

EphA3-targeted chimeric antigen receptor T cells are effective in glioma and generate curative memory T cell responses

Choice of activation protocol impacts the yield and quality of CAR T cell product, particularly with older individuals

“If you build it, they will come”: the convergence of funding, research and collaboration in paediatric brain cancer clinical trials

"Equity" in genomic health policies: a review of policies in the international arena.

CAR T-Cell Therapy for Glioblastoma.

HER2 chimeric antigen receptor T cell immunotherapy is an effective treatment for diffuse intrinsic pontine glioma

From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress

The landscape of genomic structural variation in Indigenous Australians

Indigenous Australian genomes show deep structure and rich novel variation

Endogenous H3.3K27M derived peptide restricted to HLA-A∗02:01 is insufficient for immune-targeting in diffuse midline glioma

Synthetic biology, genetic circuits and machine learning: a new age of cancer therapy

Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma

The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells

De novo-designed transmembrane domains tune engineered receptor functions

BH3 mimetic drugs cooperate with Temozolomide, JQ1 and inducers of ferroptosis in killing glioblastoma multiforme cells

To go or not to go? Biological logic gating engineered T cells

Collaborators (21)

Terrance Johns

Katharine Drummond

Jeff Holst

Damjan Vukcevic

Brendan J. McMorran

Lisa Ebert

Graham Mann

David Ritchie

Bastien Llamas

anthony jaworowski

Brittany Dewdney

Melissa Call

David Eisenstat

Owen Siggs

Lyndon Ormond-Parker

Nicholas Gottardo

Santosh Valvi

Raelene Endersby

Janine Mohamed

Hasindu Gamaarachchi

Matthew Call

Make your next move.